RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells.
CT-guided radiofrequency ablation may be effective treatment for lung cancer.
PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating
patients who have refractory or advanced lung cancer.
- Determine the safety and toxicity of radiofrequency ablation in patients with
refractory or advanced pulmonary malignancies.
- Determine the efficacy of this treatment, in terms of local control, in these patients.
- Determine whether CT scan is a reasonable imaging assessment tool for treatment
delivery and follow-up in these patients.
OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the
tumor over 2 hours.
Patients are followed at 1, 3, 6, and 12 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
- Diagnosis of a primary or secondary intrathoracic malignancy
- Any cell type or origin
- Involving the intrapulmonary, mediastinal, or pleural/chest wall
- Inoperable primary or metastatic cancer to the lung
- Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy,
- Single or multiple lesions that are non-contiguous with vital structures or organs
- Great vessels
- Less than 5 cm in largest dimension
- Accessible via percutaneous transthoracic route
- Coagulation profile normal